Axisresearch
- Healthcare
- Mordor Intelligence
- 115 pages
- Published: 07-06-2019
Market Overview
The propelling factors for the growth of the drug discovery market include the rising prevalence of a wide range of diseases (such as cardiovascular and CNS-related disorders), rising healthcare expenditure, and upcoming patent expiration of blockbuster drugs.
The diverse range of diseases, primarily cardiovascular disease, infectious diseases, diabetes, and kidney-related complications, has a high prevalence, globally. Thus, the increasing prevalence of a diverse range of diseases among all age groups and its burden, globally, drives the demand for drug discovery and its market.
There has been an upsurge in the usage of advanced technologies, such as high throughput, bioinformatics and combinatorial chemistry for better drug candidate identification. Drug discovery has evolved significantly with emerging technologies, helping the process to become more refined, accurate, and less time consuming. Due to automation, multi-detector readers, imaging hardware and software, high-throughput screening is one of the most widely used drug discovery technologies.
In recent years, there has been a rising demand for specialty medicines that is expected to ultimately influence the small molecule drug discovery market in a positive manner, as most of the specialty medicines are small molecules.
The gradual rise in the healthcare expenditure regionally helps the new pharmaceutical technology advancement. Although with high expenditure, there is a need for redirecting the resources, the transition toward better usability of healthcare expenditure for drug development is under progress.
Scope of the Report
As per the scope of the report, drug discovery is a process, which aims at identifying a compound therapeutically useful in treating and curing diseases. Typically, a drug discovery effort addresses a biological target that has been shown to play a role in the development of the disease or starts from a molecule with interesting biological activities. In the recent past, drug discovery has evolved significantly with emerging technologies, helping the process to become more refined, accurate, and less time consuming.
Key Market Trends
Biologics Drug is the Segment that is Expected to Grow Fastest under Drug Type
A biologic drug is a product that is produced from living organisms or contains components of living organisms. Biologic drugs include a wide variety of products derived from human, animal, or microorganisms. Biologic drugs are used for the treatment of numerous diseases and conditions and are the most advanced therapies available. Biologic treatments are for autoimmune diseases, which include the treatments for rheumatoid arthritis, psoriasis, ulcerative colitis, Crohn’s disease, and a range of related disorders, and have continued to see increasing usage across geographies. The biologic drugs are expected to be fueled by innovations in oncology, autoimmune, and diabetes treatments, with particular important opportunities for biologics in the oncology and autoimmune sectors.
The increasing applications of small molecule drugs for the treatment of chronic diseases are leading to the increased demand for these drugs in the market. Moreover, due to the aforementioned factors, small molecule drugs dominate the biologics in the current healthcare market.
Asia-Pacific Holds the Fastest Growth and is Expected to Follow the Same Trend Over the Forecast Period
The Asia Pacific is the fastest-growing region, due to the presence of skilled labor at an affordable cost, the rise in disposable income, and favorable government policies that are contributing to the market growth. There has also been phenomenal growth in the outsourcing companies in the Chinese region, over the last decade, which has complemented the restructuring of the R&D that has taken place. Thus, owing to the large deals of pharmaceutical companies and more number of research being done, the market for drug discovery is expected to grow.
Competitive Landscape
The market studied has various pharmaceutical companies that are investing billions of dollars in artificial intelligence (AI), in order to make the drug discovery process significantly faster and cost efficient. The pharmaceutical and biotech companies are increasing their collaborations with contract development and manufacturing organizations; thus, playing a crucial role in the development and innovation of new drugs.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1. Introduction
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of a Diverse Range of Diseases
4.2.2 Technological Advancements and Innovations
4.2.3 Increasing Healthcare Expenditure
4.2.4 Patent Expiration of Blockbuster Drugs
4.3 Market Restraints
4.3.1 Huge Capital Investment with Low-profit Margins
4.3.2 Stringent Government Regulations
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. Market Segmentation
5.1 By Drug Type
5.1.1 Small Molecule Drug
5.1.2 Biologic Drug
5.2 By Technology
5.2.1 High Throughput Screening
5.2.2 Biochips
5.2.3 Bioinformatics
5.2.4 Pharmacogenomics and Pharmacogenetics
5.2.5 Combinatorial Chemistry
5.2.6 Nanotechnology
5.2.7 Spectroscopy
5.2.8 Metabolomics
5.2.9 Other Technologies
5.3 By Service
5.3.1 Drug Metabolism and Pharmacokinetics (DMPK) Services
5.3.2 Pharmaceutical Services
5.3.3 Chemical Services
5.3.4 Biological Services
5.4 By End User
5.4.1 Research Institutes
5.4.2 Pharmaceutical Companies
5.4.3 Contract Research Organizations(CROs)
5.4.4 Other End Users
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 United Kingdom
5.5.2.2 Germany
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East & Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East & Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6. Competitive Landscape
6.1 Company Profiles
6.1.1 Pfizer Inc.
6.1.2 GlaxoSmithKline PLC
6.1.3 Merck & Co. Inc.
6.1.4 Agilent Technologies Inc.
6.1.5 Eli Lilly and Company
6.1.6 F. Hoffmann-La Roche Ltd
6.1.7 Bayer AG
6.1.8 Abbott
6.1.9 AstraZeneca PLC
6.1.10 Shimadzu Corp.
7. Market Opportunities and Future Trends
By Drug Type
- Small Molecule Drug
Biologic Drug
By Technology
High Throughput Screening
Biochips
Bioinformatics
Pharmacogenomics and Pharmacogenetics
Combinatorial Chemistry
Nanotechnology
Spectroscopy
Metabolomics
Other Technologies
By Service
Drug Metabolism and Pharmacokinetics (DMPK) Services
Pharmaceutical Services
Chemical Services
Biological Services
By End User
Research Institutes
Pharmaceutical Companies
Contract Research Organizations(CROs)
Other End Users - Geography
North America
United States
Canada
Mexico
Europe
United Kingdom
Germany
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America